Dimethyl fumarate for treating relapsing multiple sclerosis

Expert Opinion on Drug Safety

Volumn 14, Issue 1, 2015, Pages 161-170

  Sheremata, William ^a   Brown, Andrew D ^a,b   Rammohan, Kottil W ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Dimethyl fumarate; Fumarate; Lymphopenia; Monoethyl fumarate; Multiple sclerosis; Neuroprotection; Nuclear factor (erythroid derived 2) like 2; Progressive multifocal encephalopathy

Indexed keywords

FUMARIC ACID DIMETHYL ESTER; ESTER; FUMARIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL PAIN; DIARRHEA; DRUG APPROVAL; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERYTHEMA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; PREGNANCY OUTCOME; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PSORIASIS; RASH; REVIEW; SKIN DISEASE; VASCULAR DISEASE; VOMITING; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

ESTERS; FUMARATES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84918549243     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.977251     Document Type: Review

References (66)

1. Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 1965;123:552-68
2. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-52
3. Ascherio A, Munger KL, Luenemann JD. The initiation and prevention of multiple sclerosis. Nat Rev Neurol 2012;8:202-612
4. Hauser SL, Chan JR, Oksenberg JR. Multiple sclerosis: prospects and promise. Ann Neurol 2013;74:317-27
5. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. 1. Clinical results of a multicenter, randomized, double blind, placebocontrolled trial. Neurology 1993;43:655-61
6. Paty DW, Li DK; the UBC MS/MRI Group and the IFN Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993;42:662-7
7. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94
8. Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon beta-1a on Neurologic disability in relapsing multiple sclerosis. Neurology 1997;49:358-63
9. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsingremitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-76
10. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate (Copaxone) in multiple sclerosis patients observed for 6 years. Mult Scler 2000;6:255-66
11. PRISMS (Prevention of Relapses and Disability by Interferon b-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-blind placebo-controlled study of interferon b- 1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504
12. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002;59:1496-506
13. Immunex Corp. Briefing document on mitoxantrone (Novantrone) for treatment of multiple sclerosis: on file with the FDA. Available from: www.fda.gov/ohrms/dockets/ac/00/backbgrd/3582b1k. pdf [Accessed 30 July 2014
14. Hartung HP, Gonsette R, Koenig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicenter trial. Lancet 2002;360:21018-2025
15. Polman CH, OConnor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing remitting multiple sclerosis. N Engl J Med 2006;334:899-910
16. Rudick RA, Stuart WH, Calabrese PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23
17. Kappos L, Radue EW, OConnor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
18. Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 2011;10:520-9
19. OConnor PW, Li D, Freedman MS, et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006;66:894-900
20. OConnor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365(14):1293-303
21. Fox RJ, Miller DH, Phillips T, et al. Placebo-controlled Phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
22. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;d367:1098-107
23. Ropper AH. The Poison Chair treatment for multiple sclerosis. N Engl J Med 2012;367:1149-50
24. Gold R. PML with novel immunotherapies: is there light at the end of the tunnel?. Mult Scler 2014;20(S1):32; PS6.abstract
25. Ermis U, Weis J, Schultz JB. PML in a patient treated with fumaric acid. N Engl J Med 2013;368:1657-8
26. Van Oosten BW, Killestein J, Barkof F, et al. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013;368:1658-9
27. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 2012;64:3043-51
28. Sweeetser MT, Dawson KT, Bozic C. Manufacturers response to case reports of PML. N Engl J Med 2013;368:1659-61
29. Mrowietz U, Reich K. Case reports of PML in patients treated for psoriasis. N Engl J Med 2013;368:1080-1
30. Stoppe M, Thoma E, Liebert UG, et al. Cerebellar manifestations of PML under fumarate and after efalizumab treatment of psoriasis. J Neurol 2014;261(5):1021-4
31. Mohrregh-Kaiabani D, Linker RA, Gold R, Stangel M. Fumaric acid and its esters: an emerging treatment for multiple sclerosis. Curr Neuropharmacol 2009;7:60-4
32. Krebs/Citric acid cycle. Available from: www.youtube.com/watch?. v=juM2ROSLWfw [Accessed 13 September 2014] Online review
33. Ormerod AD, Mrowietz U. Fumaric acid esters, their place in the treatment of psoriasis. Br J Dermatol 2004;150:630-2
34. Schimrigk S, Brune N, Hellwig K, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label baseline-controlled pilot trial. Eur J Neurol 2006;13:604-10
35. Wierincka A, Breve J, Mercier D, et al. Detoxification enzyme inducers modify cytokine production in rat mixed glial cells. J Neuroimmunol 2005;166:132-43
36. Arnold HM, Huang C, Huang R, et al. Neuroprotective effects of BG-12 on malonate-induced striatal lesion volume in Sprague-Dawley rat brain [Poster P02- 121]. Presented at American Academy of Neurology 64th Annual Meeting; 21 - 28 April 2012; New Orleans LA
37. Nguyen T, Nioi P, Pickett CB. The Nrft2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 2009;284:13291-5
38. Linker RA, Lee D-H, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011;134:678-92
39. Lee DH, Gold R, Linker RA. Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation with fumaric acid esters. Int J Med Sci 2012;13(9):11783-803
40. Scannevin RH, Huang BB, Tedictty S, et al. BG-12 (Dimethyl fumarate) in neuroprotective in the murine cuprizone/rapamycin model of demyelination and neurodegeneration [Poster P05.164]. Programme of the 64th American Academy of Neurology Annual Meeting; 21 - 28 April 2012; New Orleans LA
41. Litjens NHR, Rademaker M, Ravensbergen B, et al. Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur J Immunol 2004;34:565-75
42. Ghoreschi K, Bruck J, Kellerer C, et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 2011;208(11):2291-303
43. Peng H, Guerau-de-Arellano M, Mehta VB, et al. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kB (NF-kB) and extracellular signal-regulated kinase 1 and 2 (ERK 1/2) and mitogen stress-activated kinase 1 and 2 (1/2) signaling. J Biol Chem 2012;287:28017-26
44. Schilling S, Goelz S, Linker R, et al. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol 2006;145:101-7
45. Wilms H, Sievers J, Rickert U, et al. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1b TNFa, and IL-6 in an in-vitro model of brain inflammation. J Neuroinflammation 2010;7:30
46. Schmidt MM, Dringen R. Fumaric acid diesters deprive cultured primary astrocytes rapidly of glutathione. Neurochem Int 2010;57:460-7
47. Gold R, Linker RA, Stangel M. Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action. Clin Immunol 2010;142:44-8
48. Bacharach-Buhles M, Pawlak FM, Matthes U, et al. Fumaric acid esters (FAEs) suppress CD 15 and ODP 4-positive cells in psoriasis. Acta Derm Venereol Suppl (Stockh) 1994;186:79-82
49. Chen H, Assmann JC, Krenz A, et al. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarates protective effect in EAE. J Clin Invest 2014;124:2188-92
50. Biogen Idec BG-12 Investigators. Brochure: IB-V7-MS-Final-30-April-2012.pdf. Available from: www.accessdata.fda.gov/drugsatfda-docs/nda/2013/204063Orig1s000PharmR.pdf [Accessed 30 July 2014
51. Ransahoff RM, Brown MA. Innate immunity in the central nervous system. J Clin Invest 2012;122:1154-71
52. Belazzi A, Nardis C, Anzivino E, et al. Human polyomavirus JC reactivation and pathogenic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies. J Neurovirol 2012;18:1-11
53. Fox RJ, Miller DH, Phillips JT, et al. Clinical efficacy of BG-12 (Dimethyl fumarate) in relapsing-remitting multiple sclerosis (RRMS): an integrated analysis of the phase3 DEFINE and CONFIRM Studies [Poster 07.097]. Programme of the American Academy of Neurology Annual Meeting; 21 - 28 April 2012; New Orleans, LA; 2013
54. Kansanen E, Kuosmanen SM, Leinonen H, Levonen A-L. The Keap1- Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol 2013;1:45-9
55. Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicenter, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008;372:1483-72
56. Biogen-Idec Exhibit presentation at American Academy of Neurology 66th Annual Meeting; 26 April - 3 May 2014; Philadelphia, -RFPART
57. Kappos L, Gold R, Arnold DL, et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE Study. Mult Scler 2014;20:240-52
58. PRISMS-4: long-term efficacy of interferon-b-1a in relapsing MS. Neurology 2001;58:1628-36
59. Mikol DD, Barkhof M, Change P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the Rebif vs. glatiramer acetate in relapsing MS disease [REGARD] study): a multicenter, randomised, parallel, openlabel trial. Lancet Neurol 2008;7:903-14
60. OConnor P, Filippi M, Arnason B, et al. 250 μg or 500 μg interferon beta- 1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective randomised, muticentre study. Lancet Neurol 2009;8:889-97
61. Bosca I, Pascual AM, Casanova B, et al. Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone. Neurology 2008;71:457-8
62. Kiesseler BC, Jeffrey DR. Chemotherapeutics in the treatment of multiple sclerosis. Ther Adv Neurol Disord 2010;3(5):277-91
63. Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;4):438-46
64. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumabassociated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-80
65. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm366529.htm [Accessed 13 September 2014
66. Putzki N, Clifford DB, Bischof D, et al. Characteristics of PML cases in multiple sclerosis patients switching to fingolimod from natalizumab. Mult Scler 2014;20(S1):43; ECTRIMS2014 Abstr. FC3